几种甲型H1N1流感病毒SYBRGreenI荧光RT—PCR检测方法的验证

目的比较和验证5种甲型H1N1流感病毒SYBRGreenI荧光RT—PCR检测方法。方法首先使用美国NCBI网站的Primer—BLAST程序验证5种甲型H1N1流感病毒SYBRGreenI荧光RT—PCR检测方法引物的理论特异性,然后使用猪流感H1N1病毒核酸、2009年新甲型H1N1流感病毒核酸、H5N1禽流感核酸、能力验证样品作为试验样品验证方法的实验特异性。结果理论验证结果显示5对来源于文献的引物均适合于猪流感的检测,前3对可用于新型甲型H1Nl流感的检测,但只限于个别来源的毒株,与预期略有差别。实验验证结果显示,方法l可正确检出甲型流感病毒;方法2可正确检出猪流感H1N1亚型病毒、新甲型H1N1流感病毒核酸;方法3检测新甲型H1N1流感核酸时未获得阳性结果;方法4可以正确检测出猪流感H1病毒核酸;方法5可以正确检测出猪流感H1N1病毒核酸,但检测新甲型H1N1流感核酸、禽流感H5N1核酸时也为阳性。结论方法1可用于猪甲型流感和新甲型H1N1流感病毒的初筛;方法2可用于猪流感H1N1亚型病毒和新甲型H1N1流感病毒核酸的初筛;方法3不适合新甲型H1N1流感病毒核酸的检测;方法4可用于猪流感H1亚型的检测;方法5不适合于猪流感H1N1亚型病毒的检测。采用SYBRGreenI荧光RT—PCR方法检测甲型H1N1流感病毒核酸,特异性普遍不十分理想,只能用于初筛检测。     

甲型H1N1流感病毒基因组序列分析及其特性研究

目的 分析甲型H1N1流感病毒的基因组序列特征,阐明该毒株的遗传变异及分子特性.方法 GenBank中获取流感病毒全序列,对各段基因与已知序列进行分析比较,绘制进化树,并分析和预测甲型毒株的致病性、药物敏感性和现有疫苗的预防保护作用.结果 甲型H1N1病毒的HA、PB2、PB1、PA、NP、NS基因与美国本土的猪流感病毒序列具有高度同源性,NA和M基因具有典型的欧亚株系猪流感病毒特征.该病毒具有人传人的分子基础,HA上HA1和HA2裂解位点序列为PSIQSR↓+GLFGAI,尚不具备高致病性流感病毒的特征.病毒对金刚烷胺类药物耐药,而对达菲和扎那米韦敏感.HA片段5个抗原决定区氨基酸序列与人用流感疫苗具有较大差异,推测现有疫苗对预防本次疫情基本无效.结论 甲型H1N1是一种北美和欧亚两种猪流感病毒的混合体,开发针对本病毒的流感疫苗有助于进一步控制疫情蔓延.     

An elastase-dependent attenuated heterologous swine influenza virus protects against pandemic H1N1 2009 influenza challenge in swine

Influenza virus infections continue to cause production losses in the agricultural industry in addition to being a human public health concern. The primary method to control influenza is through vaccination. However, currently used killed influenza virus vaccines must be closely matched to the challenge virus. The ability of an elastase-dependent live attenuated influenza A virus was evaluated to protect pigs against the pandemic H1N1 2009 influenza virus. Pigs vaccinated intranasally or intratracheally with the elastase-dependent swine influenza virus (SIV) vaccine had significantly reduced macroscopic and microscopic lung lesions and lower viral loads in the lung and in nasal swabs. Thus, elastase-dependent SIV mutants can be used as live-virus vaccines against swine influenza in pigs. In addition, low levels of cross-neutralizing antibodies to H1N1 2009 were elicited prior to challenge by the swine adapted H1N1 avian strain vaccine.     

Efficacy of inactivated swine influenza virus vaccines against the 2009 A/H1N1 influenza virus in pigs

The gene constellation of the 2009 pandemic A/H1N1 virus is a unique combination from swine influenza A viruses (SIV) of North American and Eurasian lineages, but prior to April 2009 had never before been identified in swine or other species. Although its hemagglutinin gene is related to North American H1 SIV, it is unknown if vaccines currently used in U.S. swine would cross-protect against infection with the pandemic A/H1N1. The objective of this study was to evaluate the efficacy of inactivated vaccines prepared with North American swine influenza viruses as well as an experimental homologous A/H1N1 vaccine to prevent infection and disease from 2009 pandemic A/H1N1. All vaccines tested provided partial protection ranging from reduction of pneumonia lesions to significant reduction in virus replication in the lung and nose. The multivalent vaccines demonstrated partial protection; however, none was able to prevent all nasal shedding or clinical disease. An experimental homologous 2009 A/H1N1 monovalent vaccine provided optimal protection with no virus detected from nose or lung at any time point in addition to amelioration of clinical disease. Based on cross-protection demonstrated with the vaccines evaluated in this study, the U.S. swine herd likely has significant immunity to the 2009 A/H1N1 from prior vaccination or natural exposure. However, consideration should be given for development of monovalent homologous vaccines to best protect the swine population thus limiting shedding and the potential transmission of 2009 A/H1N1 from pigs to people.     

Pandemic (H1N1) 2009 Infection in Swine Herds, Manitoba, Canada

In Manitoba, Canada, several swine herds were infected by pandemic (H1N1) 2009 virus in the summer of 2009. Results of several investigations concluded that outbreaks of infection with this virus are similar in duration to outbreaks of infections with swine influenza viruses A (H1N1) and A (H3N2).     

Protective efficacy of an inactivated Eurasian avian-like H1N1 swine influenza vaccine against homologous H1N1 and heterologous H1N1 and H1N2 viruses in mice

Eurasian avian-like H1N1 (EA H1N1) swine influenza viruses are prevalent in pigs in Europe and Asia, but occasionally cause human infection, which raises concern about their pandemic potential. Here, we produced a whole-virus inactivated vaccine with an EA H1N1 strain (A/swine/Guangxi/18/2011, SW/GX/18/11) and evaluated its efficacy against homologous H1N1 and heterologous H1N1 and H1N2 influenza viruses in mice. A strong humoral immune response, which we measured by hemagglutination inhibition (HI) and virus neutralization (VN), was induced in the vaccine-inoculated mice upon challenge. The inactivated SW/GX/18/11 vaccine provided complete protection against challenge with homologous SW/GX/18/11 virus in mice and provided effective protection against challenge with heterologous H1N1 and H1N2 viruses with distinctive genomic combinations. Our findings suggest that this EA H1N1 vaccine can provide protection against both homologous H1N1 and heterologous H1N1 or H1N2 virus infection. As such, it is an excellent vaccine candidate to prevent H1N1 swine influenza.     

长沙市甲型H1N1流感病毒神经氨酸酶基因序列分析

目的对长沙市甲型H1N1流感病毒A/changsha/78/2009的神经氨酸酶（neuraminidase,NA）基因进行测序分析,以期了解该病毒的来源及变异情况。方法利用国家流感中心（CNIC）和世界卫生组织（WHO）推荐的NA基因测序引物和CEQTM8000 Genetic Analysis System对2009年长沙市甲型H1N1流感患者阳性鼻咽拭子标本（A/changsha/78/2009）进行测序,测序结果提交至GenBank并利用Lasergene和Mega5软件对测序结果进行氨基酸比对和进化树分析。结果 A/changsha/78/2009 NA基因GenBank登录号为：GQ463958.1,与瑞典斯德哥尔摩甲型H1N1流感病毒分离株A/Stockholm/37/2009（H1N1）核苷酸同源性为100%;进化树分析显示A/changsha/78/2009 NA基因属于欧亚猪流感分支,包含A/changsha/78/2009在内的甲型H1N1流感病毒与A/swine/Spain/WVL6/1991（H1N1）亲缘关系近;A/chang-sha/78/2009与A/swine/Spain/WVL6/1991 NA基因均有7个潜在糖基化位点,A/changsha/78/2009 NA基因未发生H274Y位点突变。结论包含A/changsha/78/2009在内的甲型H1N1流感病毒NA基因可能来源于欧亚猪流感病毒,A/changsha/78/2009病毒对神经氨酸酶抑制剂类药物敏感。     

Reassortant Influenza A(H1N1)pdm09 Virus in Elderly Woman,Denmark, January 2021

A case of human infection with influenza A(H1N1)pdm09 virus containing a nonstructural gene highly similar to Eurasian avian-like H1Nx swine influenza virus was detected in Denmark in January 2021. We describe the clinical case and report testing results of the genetic and antigenic characterizations of the virus.     

甲型H1N1流行性感冒病毒血凝素蛋白基因进化研究

推算全球各地近年来分离的甲型H1N1流行性感冒(简称流感)病毒株血凝素(HA)蛋白片段的进化速率和进化分歧时间,从而初步探索流感病毒的起源和传播关系.方法搜集GenBank数据库中2008年以来登录的全球流感病毒H1序列共344条(人源性248条,猪源性84条,禽源性11条,其他1条)及本课题组分离的7条人源性H1序列,按照"分子钟"进化理论和基于markov chain monte carlo(MCMC)算法的Bayesian推断方法估算进化速率和进化分歧时间,并利用后验概率方法构建系统进化树.结果 系统进化树显示,美国人源性、猪源性与禽源性H1序列与部分亚洲猪源性H1序列构成一个主要分支(美国分支);全球其他地区的人源性H1序列构成另一个主要分支(欧亚人分支);而部分中国猪源性、禽源性H1序列与意大利分离的禽源性序列也构成一个分支(欧亚动物分支).全球H1N1和H1N2流感病毒株H1序列930 bp核苷酸序列的年平均进化速率约为2.57×10-3/位点(95%最高后验概率区间:1.96×10-33.03×10-3/位点).其中,欧洲人源性H1序列和中国大陆猪H1序列的起源时间最早,年进化速率分别为6.46×10-3/位点、0.97×10-3/位点;而美国的人源性与猪源性H1序列的起源时间相近,年进化速率则分别为5.86×10-3/位点、5.02×10-3/位点.结论 本次甲型H1N1流感暴发是北美地区H1N1病毒株长期人畜共患性积累的基因变异所致.中国大陆地区并非本次流感疫情病毒株的发源地,尚无证据能够表明北美暴发株属于一个全新的流感病毒变种.     

Seroconversion to pandemic (H1N1) 2009 virus and cross-reactive immunity to other swine influenza viruses

To assess herd immunity to swine influenza viruses, we determined antibodies in 28 paired serum samples from participants in a prospective serologic cohort study in Hong Kong who had seroconverted to pandemic (H1N1) 2009 virus. Results indicated that infection with pandemic (H1N1) 2009 broadens cross-reactive immunity to other recent subtype H1 swine viruses.     

Novel swine influenza virus subtype H3N1, United States

Influenza A virus infects various animal species and transmits among different hosts, especially between humans and swine. Swine may serve as a mixing vessel to create new reassortants that could infect humans. Thus, monitoring and characterizing influenza viruses in swine are important in preventing interspecies transmission. We report the emergence and characterization of a novel H3N1 subtype of swine influenza virus (SIV) in the United States. Phylogenetic analysis showed that the H3N1 SIVs may have acquired the hemagglutinin gene from an H3N2 turkey isolate, the neuraminidase gene from a human H1N1 isolate, and the remaining genes from currently circulating SIVs. The H3N1 SIVs were antigenically related to the turkey virus. Lung lesions and nasal shedding occurred in swine infected with the H3N1 SIVs, suggesting the potential to transmit among swine and to humans. Further surveillance will help determine whether this novel subtype will continue to circulate in swine populations.     

Human Infection with Eurasian Avian-Like Swine Influenza A(H1N1) Virus,the Netherlands,September 2019

We report a zoonotic infection of a pig farmer in the Netherlands with a Eurasian avian-like swine influenza A(H1N1) virus that was also detected in the farmed pigs. Both viruses were antigenically and genetically characterized. Continued surveillance of swine influenza A viruses is needed for risk assessment in humans and swine.     

Novel Reassortant Influenza A(H1N2) Virus Derived from A(H1N1)pdm09 Virus Isolated from Swine,Japan, 2012

We isolated a novel influenza virus A(H1N2) strain from a pig on January 13, 2012, in Gunma Prefecture, Japan. Phylogenetic analysis showed that the strain was a novel type of double-reassortant virus derived from the swine influenza virus strains H1N1pdm09 and H1N2, which were prevalent in Gunma at that time.     

Reassortant Pandemic (H1N1) 2009 virus in pigs, United Kingdom

Surveillance for influenza virus in pigs in the United Kingdom during spring 2010 detected a novel reassortant influenza virus. This virus had genes encoding internal proteins from pandemic (H1N1) 2009 virus and hemagglutinin and neuraminidase genes from swine influenza virus (H1N2). Our results demonstrate processes contributing to influenza virus heterogeneity.     

Genomic Signatures of Influenza A Pandemic (H1N1) 2009 Virus

Adaptive mutations that have contributed to the emergence of influenza A pandemic (H1N1) 2009 virus, which can replicate and transmit among humans, remain unknown. We conducted a large-scale scanning of influenza protein sequences and identified amino acid–conserving positions that are specific to host species, called signatures. Of 47 signatures that separate avian viruses from human viruses by their nonglycoproteins, 8 were human-like in the pandemic (H1N1) 2009 virus. Close examination of their amino acid residues in the recent ancestral swine viruses of pandemic (H1N1) 2009 virus showed that 7 had already transitioned to human-like residues and only PA 356 retained an avian-like K; in pandemic (H1N1) 2009 virus, this residue changed into a human-like R. Signatures that separate swine viruses from human viruses were also present. Continuous monitoring of these signatures in nonhuman species will help with influenza surveillance and with evaluation of the likelihood of further adaptation to humans.     

Pandemic (H1N1) 2009 Virus on Commercial Swine Farm, Thailand

A swine influenza outbreak occurred on a commercial pig farm in Thailand. Outbreak investigation indicated that pigs were co-infected with pandemic (H1N1) 2009 virus and seasonal influenza (H1N1) viruses. No evidence of gene reassortment or pig-to-human transmission of pandemic (H1N1) 2009 virus was found during the outbreak.     

Serologic Cross-Reactivity with Pandemic (H1N1) 2009 Virus in Pigs, Europe

We tested serum samples from pigs infected or vaccinated with European swine influenza viruses (SIVs) in hemagglutination-inhibition assays against pandemic (H1N1) 2009 virus and related North American SIVs. We found more serologic cross-reaction than expected. Data suggest pigs in Europe may have partial immunity to pandemic (H1N1) 2009 virus.     

Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus

Swine influenza A virus (SwIV) infection has considerable economic and animal welfare consequences and, because of the zoonotic potential, can also have public health implications. The 2009 pandemic H1N1 ‘swine-origin’ infection is now endemic in both pigs and humans. In Europe, avian-like H1_avN1, human-like H1_huN2, human-like swine H3N2 and, since 2009, pandemic H1N1 (pH1N1) lineage viruses and reassortants, constitute the dominant subtypes. In this study, we used a swine pH1N1 challenge virus to investigate the efficacy of whole inactivated virus vaccines homologous or heterologous to the challenge virus as well as a commercial vaccine. We found that vaccine-mediated protection was most effective when vaccine antigen and challenge virus were homologous and correlated with the specific production of neutralising antibodies and a cellular response to the challenge virus. We conclude that a conventional whole inactivated SwIV vaccine must be antigenically matched to the challenge strain to be an effective control measure.     

Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus

In 2009 a new influenza A/H1N1 virus strain (“pandemic (H1N1) 2009”, H1N1v) emerged that rapidly spread around the world. The virus is suspected to have originated in swine through reassortment and to have subsequently crossed the species-barrier towards humans. Several cases of reintroduction into pigs have since been reported, which could possibly create a reservoir for human exposure or ultimately become endemic in the pig population with similar clinical disease problems as current swine influenza strains. A soluble trimer of hemagglutinin (HA), derived from the H1N1v, was used as a vaccine in pigs to investigate the extent to which this vaccine would be able to protect pigs against infection with the H1N1v influenza strain, especially with respect to reducing virus replication and excretion. In a group of unvaccinated control pigs, no clinical symptoms were observed, but (histo)pathological changes consistent with an influenza infection were found on days 1 and 3 after inoculation. Live virus was isolated from the upper and lower respiratory tract, with titres up to 10⁶ TCID₅₀ per gram of tissue. Furthermore, live virus was detected in brain samples. Control pigs were shedding live virus for up to 6 days after infection, with titres of up to 10⁵ TCID₅₀ per nasal or oropharyngeal swab. The soluble H1N1v HA trimer diminished virus replication and excretion after a double vaccination and subsequent challenge. Live virus could not be detected in any of the samples taken from the vaccinated pigs. Vaccines based on soluble HA trimers provide an attractive alternative to the current inactivated vaccines.     

Co-circulation of pandemic 2009 H1N1, classical swine H1N1 and avian-like swine H1N1 influenza viruses in pigs in China

The pandemic A/H1N1 influenza viruses emerged in both Mexico and the United States in March 2009, and were transmitted efficiently in the human population. They were transmitted occasionally from humans to other mammals including pigs, dogs and cats. In this study, we report the isolation and genetic analysis of novel viruses in pigs in China. These viruses were related phylogenetically to the pandemic 2009 H1N1 influenza viruses isolated from humans and pigs, which indicates that the pandemic virus is currently circulating in swine populations, and this hypothesis was further supported by serological surveillance of pig sera collected within the same period. Furthermore, we isolated another two H1N1 viruses belonging to the lineages of classical swine H1N1 virus and avian-like swine H1N1 virus, respectively. Multiple genetic lineages of H1N1 viruses are co-circulating in the swine population, which highlights the importance of intensive surveillance for swine influenza in China.